NEWS & ARCHIVE

Additional Financing 2025

In the first quarter of 2025, existing and new investors have committed and paid-in an additional € 4.4 million in a second and third Closing of the financing which already started in 2023 and thus could be increased to a total volume of € 6.8 million. With this additional financing, Zytoprotec Flexible Kapitalgesellschaft has reached a total of more than 60 direct shareholders. We would like to thank all investors for their great engagement and trust into Zytoprotec.

Successful Financing 2023

Around EUR 2.5 million in fresh investor capital was raised in 2023, most of it in December. The Zytoprotec team is delighted that this was possible despite the difficult financing environment for start-ups during the last two years. And we would like to thank all new investors for the trust they have placed in us. The money will primarily be used for further research, possibly for a small Austrian Phase 2b Study to substantiate the recently discovered systemic anti-inflammatory effect of our lead product PDprotec^®, ...

> read more

PDprotec^® Researchers at EuroPD

November 2023, EuroPD in Bruges, Belgium – Three Researchers instrumental in developing Zytoprotec’s innovative PD-fluid PDprotec® were invited as speakers to EuroPD:  Christoph Aufricht, Zytoprotec’s co-founder and CSO (keynote), Rebecca Herzog and Klaus Kratochwill. EuroPD (Nov. 27-30, 2023, in Bruges, Belgium).

Successful next steps towards implementation of Chinese Joint Venture

In September 2023, a Zytoprotec team visited Vantage Group in Shanghai. The week-long visit comprised successful meetings with potential investors who all showed high interest in financing the JV, a high-ranking official of the Chinese Pharmaceutical Regulator (cFDA), Tigermed, Asia’s largest and highly regarded CRO (Contract Research Organization) and a supplier of bags for the envisaged Clinical Phase III Study.

Zytoprotec signs MoU and TS with Chinese Joint Venture partner

In August 2023, Zytoprotec signed a Memorandum of Understanding as well as a Term Sheet with its envisaged Chinese JV partner Vantage Group, Shanghai. The JV is scheduled to be set up by the end of 2023. Its purpose will be the sponsorship of a Chineses Clinical Phase III Trial regarding Zytoprotec’s lead product PDprotec®, whereby the trial shall commence at the end of 2024. If successful, the JV will produce and sell PDprotec® in China and possibly neighboring countries.

Patent Filed for New Indications

In March 2023, Zytoprotec filed an application for a new patent protecting its discovery of the anti-inflammatory effect of PDprotec® with the European Patent Office (EPO). In September 2023, the EPO confirmed in writing that the discovery is “new” and “innovative”, thus making it almost certain that the respective patent will be granted in due course.

Capital market prospectus 2022

Vienna, Europe, October 2022 – For an investment in a share in the Private Limited Company (GmbH) of the issuer to be newly issued and held in trust and/or in a new atypical silent partnership with the issuer, to be entered into in trust, investors can obtain subscription forms online on the platform www.join-zytoprotec.at. In both investments the minimum subscription is 5,000 EUR. The subscription volume of both investment will amount to less than 5 mio. EUR. The offer period starts on 17th of October 2022 and will end with the expiry of 16th of October 2023. Click here to find our 2022 capital market prospectus and its first addendum (March 2023) (only german). 

Zytoprotec Phase II Peritoneal Dialysis Study: Last Patient Out

Vienna, Europe, November 14, 2016 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids with cytoprotective properties, announced today that the last patient has completed treatment in a Phase II study with its lead product, PDprotec® . The Company expects results of this trial to be available in the first quarter of 2017.

> read more

Zytoprotec's Novel Dialysis Product Meets Both Endpoints in Phase II Study

Vienna, Europe, June 9, 2017 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids, announced today the highly promising outcome of the Phase II study of its peritoneal dialysis fluid PDprotec^®. In this double-blind, placebo-controlled cross-over study, the two primary endpoints were successfully met.

> read more

FDA Grants Orphan Drug Designation to Zytoprotec's Novel Dialysis Fluid

Vienna, Europe, December 14, 2017 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids, announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to PDprotec^®, the Company's peritoneal dialysis fluid for the treatment of patients with end-stage renal disease (kidney failure).

> read more

Neue Therapieansätze für eine Verbesserung der Bauchfelldialyse

Christian Doppler Labor „Molekulare Stressforschung in der Peritonealdialyse“ an der MedUni Wien eröffnet – Förderung durch Wissenschafts-, Forschungs- und Wirtschaftsministerium

> read more

Zytoprotec with a New Management Team

Vienna (OTS) - With a new management team, the Viennese biotech company has positioned itself for the final spurt in the extremely important phase II study in the development of its main product, an innovative dialysis fluid for the treatment of severe kidney failure.

> read more